No­var­tis yanks ap­pli­ca­tion from the EMA af­ter reg­u­la­tors say re­searchers nev­er proved ef­fi­ca­cy of their $3.4B dry eye drug

No­var­tis is throw­ing in the tow­el on its cam­paign to get their dry eye dis­ease drug Xi­idra (li­fite­grast) ap­proved in Eu­rope af­ter reg­u­la­tors con­clud­ed that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER